This is the latest episode of the free DDW narrated podcast, “Outside the box thinking for drug discovery success”, which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Stanford researchers construct the most complete synthetic microbiome, … Read More
This is the latest episode of the free DDW narrated podcast, “Outside the box thinking for drug discovery success”, which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Stanford researchers construct the most complete synthetic microbiome, … Read More
DDW’s Megan Thomas attended PEGS Europe 2023 in Lisbon, Portugal, from Tuesday 14 November to Thursday 16 November 2023. Here, she shares insight from the annual biologics technology meeting. Scientific tracks and presentations Antibody-based cancer therapies The first presentation attended in the antibody-based cancer therapies… Read More
DDW’s Megan Thomas speaks to Jennifer Cann, Director of Pathology at Virscio, a company solving human health challenges through biomedical research. MT: Can you provide a top line summary of your research? JC: As Virscio’s Director of Pathology, I provide exploratory and translational pathology support for… Read More
Scientists at the University of Bath have developed a way of joining up the head and tail of a protein, making it more stable and easier to get into cells. This new tool may help researchers develop new pharmaceuticals in a cleaner, greener, and less expensive way. Drug treatments often… Read More
The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The pivotal proof-of-concept testing clears the way to progress the Clamp2 technology in a range of research programmes. … Read More
AstraZeneca has announced that the National Institute for Health and Care Excellence (NICE) has recommended Imfinzi (durvalumab) in combination with gemcitabine and cisplatin (chemotherapy) for NHS use in England and Wales for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).1… Read More
This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More
This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and… Read More
CN Bio, an organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards. The award recognises the ongoing success of the company’s collaboration with the US Food and Drug Administration… Read More
Minoryx has announced enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in the US Phase III clinical trial, CALYX. As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-linked Adrenoleukodystrophy (X-ALD) patients with cALD. In June… Read More
The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. YORVIPATH is Ascendis Pharma’s prodrug of parathyroid hormone (PTH 1-34), administered once daily. Ascendis plans its first EU launch of YORVIPATH in January 2024… Read More
The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an SABCS cosponsor, will award two researchers for their significant contributions to breast cancer research at SABCS 2023, 5-9 December, at the Henry B González Convention Center in San Antonio, Texas. 2023… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The breaking news this week was certainly the first regulatory approval for… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The breaking news this week was certainly the first regulatory approval for… Read More
Ahead of protein and antibody engineering conference PEGS Europe 2023 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against… Read More
